Log in
Enquire now
‌

US Patent 10407411 Purified cenicriviroc and purified intermediates for making cenicriviroc

Patent 10407411 was granted and assigned to Tobira Therapeutics on September, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Tobira Therapeutics
Tobira Therapeutics
Current Assignee
Tobira Therapeutics
Tobira Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10407411
Patent Inventor Names
Pasit Phiasivongsa0
Nicholas Morra0
Date of Patent
September 10, 2019
Patent Application Number
15628968
Date Filed
June 21, 2017
Patent Primary Examiner
‌
Noble E Jarrell
Patent abstract

The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or salts thereof, high purity intermediates thereto and processes for synthesizing the same.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10407411 Purified cenicriviroc and purified intermediates for making cenicriviroc

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.